StreetAlpha.app
Home › Stocks › ERAS

Erasca, Inc. (ERAS)

Healthcare
$13.89
▼ −8.07%
LAST CLOSE · NOV 17

Erasca is a San Diego company developing investigational cancer drugs that target the RAS/MAPK cell signaling pathway. It last closed at $13.89 on Nov 17, down 8.07% on the day. Over the past 90 days StreetAlpha recorded 2 whale options trades in ERAS, 50% of them bullish and 50% bearish. In the past 30 days there were 3 dark pool prints totaling $4.3M, the largest $3.4M.

AI Auto Pilots
Is ERAS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$307.9M
EPS (diluted)
−$0.97
Free cash flow
−$109.2M
Valuation
Market cap
$4.9B
351.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$119.0M
At Sep 30
Shareholder equity
$916.7M
Shares outstanding
351.0M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$122.8M−$122.8MFY2021FY2022: −$242.8M−$242.8MFY2022FY2023: −$125.0M−$125.0MFY2023FY2024: −$161.7M−$161.7MFY2024FY2025: −$124.5M−$124.5MFY2025

From ERAS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ERAS in the past 90 days, not enough for a consensus
Average 12-month target
$35.00
▲ 152.0% upside

Based on 1 analyst who set a price target on ERAS in the past 90 days. The average target is $35.00, with a high of $35.00 and a low of $35.00, compared with the last close of $13.89.

$12$20$28$37PAST 10 TRADING DAYS12-MONTH TARGETSHIGH $35AVG $35LOW $35Jun 4LAST CLOSE+12 MO$12$20$28$37PAST 10 DAYSTARGETSHIGH $35AVG $35LOW $35Jun 4LAST CLOSE+12 MO
Highest target$35.00
Average target$35.00
Lowest target$35.00
Latest rating changes
Leerink PartnersInitiated
Nov 17Buy$35
B of A SecuritiesTarget raised
Aug 14Hold$18 → $20
GuggenheimMaintained
Aug 13Buy$21
HC Wainwright & Co.Maintained
Aug 12Buy$22
Morgan StanleyMaintained
Jul 20Hold$21
DateFirmActionRatingPrice target
Nov 17Leerink PartnersInitiatedBuy$35
Aug 14B of A SecuritiesTarget raisedHold$18 → $20
Aug 13GuggenheimMaintainedBuy$21
Aug 12HC Wainwright & Co.MaintainedBuy$22
Jul 20Morgan StanleyMaintainedHold$21
Loading…

Technical Analysis

ERAS · as of the Nov 17 close · updated after every close
Turning down

The stock is 7% below its 20 day and 7% below its 50 day average. It is 10% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the swing low (Oct 8) at $13.78, and the nearest resistance the Pivot at $14.39.

Short trendBearish
Long trendNeutral
MomentumNeutral
StretchNormal
VolatilityHigh, 9.1%/day
Key levels
$24.2852 week high+74.8%
$16.59100 day average+19.4%
$15.30200 day average+10.2%
$15.19Pivot R1+9.4%
$15.03Swing high (Jun 1)+8.2%
$14.8950 day average+7.2%
$14.8620 day average+7.0%
$14.39Pivot+3.6%
$13.89Last close
$13.78Swing low (Oct 8)−0.8%
$13.10Pivot S1−5.7%
$2.5252 week low−81.9%
Indicators
RSI (14)43.61Middle of its rangeNeutral
MACD0.05Above its signal lineBullish
Stochastic42.0Middle of its rangeNeutral
ADX (14)11.0No clear trend
Williams %R-81.6Oversold below −80, overbought above −20Oversold
CCI (20)-58.7Oversold below −100, overbought above 100Neutral
Rate of change−5.1%Change over 10 sessionsBearish
ATR (14)$1.26Typical daily range, 9.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ERAS

What happened before

See how ERAS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ERAS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ERAS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Aug 31 – Sep 23
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$4.3M
Largest print
$3.4M
Loading…

ERAS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲177 buying vs 95 selling
  • ▲Held by funds +13.0 pts
  • ▲Funds holding +14
  • ▲Superinvestors: 3 added, 2 cut
  • ▼Put/call 0.13 to 0.23
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding273259+5.4%
In funds' top 101314−7.1%
Held by funds93.3%80.2%+13.0 pts
New / increased43 / 13462 / 101+8.6%
Reduced / sold out65 / 3076 / 28−8.7%
Put/call ratio0.230.13+81.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ERAS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ERAS is in one of them and how their past ERAS trades turned out.

ERAS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ERAS in an article yet. Here's the latest on the wider market.

ERAS Congress Trades

All congress trades →
Trades, 12 months
1
Buys
0
0%
Sells
1
100%
People
1
Last filed Sep 30
Who traded ERAS · since 2026
Latest 1 filing
$1K – $15KTraded Jul 30, 2026Filed Sep 30, 2026
PersonTypeAmountTradedFiledDelay
Scott A KuporExecutive branchSell$1K – $15KJul 30, 2026Sep 30, 202662 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Erasca

Erasca is a biopharmaceutical company based in San Diego, California, that develops cancer treatments. Its work focuses on tumors driven by changes in the RAS/MAPK pathway, a cell signaling pathway that many cancers rely on. The company's pipeline includes investigational drugs that target RAS and other points in the pathway, given alone or in combination, aimed at patients whose cancers have few targeted treatment options. These candidates are still in clinical testing and are not yet approved for sale.

Headquarters
San Diego, CA